


Cite this: *Nanoscale Adv.*, 2019, 1, 3555

# Dual targeting of folate receptor-expressing glioma tumor-associated macrophages and epithelial cells in the brain using a carbon nanosphere–cationic folate nanoconjugate†

Chandra Kumar Elechalawar,<sup>‡ae</sup> Dwaipayan Bhattacharya,<sup>‡ad</sup> Mohammed Tanveer Ahmed,<sup>ae</sup> Halley Gora,<sup>§a</sup> Kathyayani Sridharan,<sup>ae</sup> Piyush Chaturbedy,<sup>b</sup> Sarmistha Halder Sinha,<sup>c</sup> Madhan Mohan Chandra Sekhar Jaggarapu,<sup>ae</sup> Kumar Pranav Narayan,<sup>d</sup> Sumana Chakravarty,<sup>a</sup> Muthusamy Eswaramoorthy,<sup>id b</sup> Tapas Kumar Kundu<sup>c</sup> and Rajkumar Banerjee<sup>id \*ae</sup>

Glioblastoma multiforme (GBM), the highly invasive form of glioma, exhibits the highest mortality in patients with brain malignancies. Increasing glioma patients' survivability is challenging, as targeting only tumor-associated malignant cells would not reduce the overall aggressiveness of the tumor mass. This is due to the inadequacy in countering pro-proliferative, invasive and metastatic factors released by tumor-mass associated macrophages (TAMs). Hence, strategically, dual targeting both tumor cells and TAMs is necessary for effective glioma treatment and increased survivability. Conventional FR-targeting systems can easily target cancer cells that overtly express folate receptors (FRs). However, FRs are expressed only moderately in both glioma cells and in TAMs. Hence, it is more challenging to coordinate dual targeting of glioma cells and TAMs with lower levels of FR expression. A recently developed carbon nanosphere (CSP) with effective blood–brain barrier (BBB) penetrability was modified with a new folic acid–cationic lipid conjugate (F8) as a targeting ligand. The uniqueness of the cationic lipid–folate conjugate is that it stably associates with the negatively charged CSP surface at about >22 mol% surface concentration, a concentration at least 5-fold higher than what is achieved for conventional FR-targeting delivery systems. This enabled dual uptake of the CSP on TAMs and tumor cells *via* FRs. A doxorubicin-associated FR-targeting formulation (CFD), in an orthotopic glioma model and in a glioma subcutaneous model, induced the maximum anticancer effect with enhanced average mice survivability twice that of untreated mice and without any systemic liver toxicity. Additionally, we observed a significant decrease of TAM-released pro-aggressive factors, TGF- $\beta$ , STAT3, invasion and migration related sICAM-1, and other cytokines indicating anti-TAM activity of the CFD. Taken together, we principally devised, to the best of our knowledge, the first FR-targeting nano-delivery system for targeting brain-associated TAMs and tumor cells as an efficient glioma therapeutic.

Received 29th January 2019  
Accepted 22nd July 2019

DOI: 10.1039/c9na00056a

rsc.li/nanoscale-advances

<sup>a</sup>Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, India. E-mail: banerjee@iict.res.in

<sup>b</sup>Chemistry and Physics of Materials Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur P.O., Bangalore, 560 064, India

<sup>c</sup>Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur P.O., Bangalore, 560 064, India

<sup>d</sup>Department of Biological Sciences, BITS Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet Mandal, Hyderabad 500078, India

<sup>e</sup>Academy of Scientific & Innovative Research (AcSIR), Taramani, Chennai 600113, India

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9na00056a

‡ Equal contributing authors.

§ Current Address: School of Veterinary Science, The University of Queensland, Gatton Campus, Queensland 4343, Australia.

## 1. Introduction

Advanced nanomaterials are needed for improved drug delivery. To utilise the substantial therapeutic potential of nanomaterials, surface functionalization is of paramount importance. Functionalization includes antibody conjugation, small molecule labelling, functionalization with biologically active targeting molecules *etc.*, thus facilitating efficient and promising imaging and therapy. Hence, the general challenge in surface modification of nanocarriers lies in designing multifunctional small molecules or fabricating bioactive large molecules.

Among brain cancers, glioblastoma multiforme (GBM), the invasive form of glioma, induces maximum mortality<sup>1</sup> in



patients. The overall aggressiveness of GBM is not only due to the tumor-associated malignant cells but also due to a special tumor-associated micro-environment (TME) created within the tumor mass. The TME consists of malignant cancer cells, various heterogeneous cell components including cancer stem cells, tumor-associated vascular endothelial cells, fibroblasts, lymphatic cells and also macrophages. These tumor-associated macrophages (TAMs), the most abundant immune cells in tumor-masses, play predominant roles in tumor proliferation, cell invasion, metastasis, angiogenesis, suppressing tumor-associated immune responses *etc.*<sup>2–4</sup> GBM-associated glioma stem cells secrete periostin which recruits tumor-supportive TAMs.<sup>5</sup> TAMs are differentiated monocytes that form in response to tumor-derived chemo-attractants such as CSF-1 (macrophage colony stimulating factor-1), various chemokines like CCL2/3/4/5/9 and VEGF. Levels of these proteins in tumor masses are proportionately related to the overall TAM count in the tumor environment,<sup>6</sup> although no correlation was established between TAM count and patient prognosis. However, the majority of studies showed that high TAM numbers are linked with reduced patient survival. Many TME-expressed factors and corresponding receptors expressed on TAMs work in tandem to maintain the overall aggressiveness. One such incidence is the involvement of the expressed CSF-1 receptor (CSF-1R) which helps in the survival of TAMs. On depletion of the CSF-1R, the intracranial GBM propagation halts.<sup>7</sup> But the TAM population does not deplete, as expression of other survival factors gains importance. Incidentally, most treated animals eventually acquire resistance to CSF-1R inhibition.<sup>8</sup> The invasiveness of a glioma tumor mass is due to functional expression of many factors including TAM-expressed TGF- $\beta$ , which in turn up-regulates STAT3 *via* IL-6 in the cells of tumor masses.<sup>9,10</sup> Clearly, the direct target should be TAMs for effective and long-term therapeutic benefits. Hence, TAM-targeting is increasingly gaining importance. Recently, TAMs have been found to act as slow-release reservoirs for nanoformulations delivering drugs to tumor masses.<sup>11</sup> However, delivery of nanoformulations through the blood–brain barrier (BBB) to *in situ* glioma masses and their TAMs is an additional challenge.

More recently, carbon nanospheres (CSPs) have been gaining attention due to their applications in various fields including drug delivery.<sup>12,13</sup> Among them, glucose-derived CSPs are emerging as a new class of intracellular drug carriers in drug delivery. The non-toxic CSPs are readily dispersible in water, can target cell nuclei and have the unique property of crossing the blood–brain barrier (BBB) *in vivo*.<sup>14</sup> Folate receptors (FRs), the glycosylphosphatidylinositol (GPI)-anchored protein, are expressed on the surface of the cell membrane and are often overtly expressed on many cancer cells including glioblastomas and also on the TAM membrane surface.<sup>15,16</sup> As a FR binds and internalises folate or folic acid into cells, folate receptor targeting delivery systems especially for targeting FR-overexpressing cancer cells are well known. With folate as a targeting ligand, FR-targeting drug/gene nanodelivery systems are tested wherein *in situ* glioma tumors are targeted.<sup>17–19</sup> Other than FR-targeting, other nanoformulations targeting gliomas

are also reported.<sup>20–22</sup> However, the importance of targeting TAMs for glioma treatment is not emphasized in those studies. There is no authentic report describing a delivery system directly targeting TAMs in tumor masses, especially those of glioma tumors through FRs.

Recently, we have developed a cationic lipid-conjugated folic acid as an FR-targeting ligand [F8, Scheme 1], which showed effective targeting ability against a melanoma model where melanoma cells express moderate to higher levels of FRs.<sup>23</sup> Using F8 as a targeting ligand, here we describe a new BBB penetrable folate ligand-associated CSP for targeting FR-expressing, tumor associated malignant cells and TAMs. This cationic lipid-conjugated folate ligand (F8) electrostatically binds to negatively charged CSPs. With a high surface concentration of F8, the targeting CSPs showed enhanced glioma cell and TAM targeting simultaneously. Armed with a model anti-cancer drug, doxorubicin (DOX), the targeting nanoformulation exhibited significant glial cell killing, glioma tumor regression, and enhanced patient survivability. Here, TAM cells could also be targeted directly. This dual strategy of targeting TAMs and malignant cells exhibited a better outcome in glioma treatment, thereby emphasizing the importance of targeting TAMs.


## 2. Experimental

### 2.1 Chemicals and general procedures

Carbon nanospheres (CSPs) were synthesized according to a previously published protocol.<sup>15</sup> Doxorubicin (DOX) was purchased from Alfa Aesar, India, and TAM isolation was performed using a Midi MACS separating kit containing a Midi MACS separator (130-042-302), LS columns (130-042-401) and CD11b micro beads (130-097-142) [Miltenyi Biotech Asia Pacific Pte Ltd, Singapore]. Folate-free RPMI-1640 medium (Cat no. 27016021) and NIR dye DIR (D12731) were purchased from Thermo Fisher Scientific, USA. A Proteome Profiler array (Mouse Cytokine Array Panel A) (ARY006) was purchased from R&D Systems, USA. Antibiotics were purchased from HiMedia, India. All the other reagents were purchased from local suppliers and used without further purification.

### 2.2 Cell culture and antibodies

The mycoplasma-free GL261 cell line was procured from the National Cancer Institute, USA, and NIH3T3 was procured from



**Scheme 1** Nanomaterial fabrication and the folate receptor-targeting molecule: (A) the fabrication strategy of CSPs for the production of DOX-associated, non-targeting (CD) and targeting (CFD) nanoformulations. (B) Structure of the F8 molecule.



the National Centre for Cell Sciences (Pune, India). Cells were cultured at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub> in air in folate free RPMI (Gibco) containing 10% fetal bovine serum (South American Origin, Gibco, USA) and 1% penicillin–streptomycin–kanamycin. 85–90% confluent cultures of cells were used in both *in vitro* and *in vivo* experiments. The antibody against FRs (sc-28997) was purchased from Santa Cruz Biotechnology. Antibodies against FR4-PE (130-102-455), F4/80-FITC (130-102-327), CD-11b FITC (130-081-201), and CD-68 (130-102-534) were purchased from Miltenyi Biotec Asia Pacific Pte Ltd, Singapore.

### 2.3 Preparation of CSP conjugates

5 mL of 1.5 mM solution of FA8 (M. wt 757 g mol<sup>−1</sup>) was made using HPLC grade methanol. 10 mg of CSPs was added to the FA8 solution and kept stirring for 12 h at room temperature. CSPs were separated by centrifuging at 10 000 rpm for 10 min. The amount of FA8 adsorbed to CSPs was calculated from the amount present in the supernatant methanol solution of FA8 obtained by measuring the absorbance at 280 nm using a spectrometer at 270 °C. A prior calibration plot was obtained by measuring the FA8 solution at different concentrations. About 40% of FA8 was adsorbed on 10 mg of CSPs. CSP-F8-DOX or CSP-DOX was prepared by adding 10 mg of CSP-FA8 or CSP to 5 mL of 2 mM methanol solution of DOX and it was stirred for 12 h at room temperature. The CSP conjugates were separated using the centrifugation method mentioned above. The amount of DOX adsorbed to CSP conjugates (CSP-FA8, CSP, and CSP-C8) was calculated by measuring the absorbance of DOX at 495 nm in the supernatant methanol solution. 20% DOX was loaded on the CSP surface.

### 2.4 Characterization of CSP conjugates

The hydrodynamic diameter size and surface charge zeta potentials of CSP-F8-DOX (CFD), CSP-DOX (CD), CSP-F8 (CF8), CSP-FA-D (CFA-D), CSP-C8-D (CC8-D) and CSP-C8 (CC8) were measured by electrophoretic mobility using either a Zeta sizer 3000 HSA (Malvern, UK) or Lite Sizer™ 500 particle analyzer (Anton Paar GMBH, Germany). Briefly, 20 µL of each CSP conjugate was suspended in 1 mL of deionised water. A brief probe sonication of the suspension of CSP conjugates for 10–15 min minimised batch-to-batch size variations of respective CSP conjugates. Hydrodynamic diameters and surface charges of the suspension of respective CSP conjugates were then measured.

### 2.5 Cellular uptake studies

Cellular uptake studies of FR targeting CSP-FA8-DOX and non-targeting control DOX containing CSPs were conducted by fluorescence microscopy and FACS analysis in GL261 cells. Cells were seeded at a density of  $5 \times 10^5$  cells per well on square coverslips in a 6-well plate before 24 h of treatment. After 3 h of treatment cells were washed with phosphate buffered saline and pictures were taken with an inverted confocal Olympus FV10i microscope.

### 2.6 *In vitro* cell viability assay/toxicity assay

Cells at a density of 5000 per well were seeded in 96-well plates and allowed to grow for 18–24 h before the treatment. Cells were treated with various conjugates carrying the drug and free non-conjugated drug and allowed to grow for 48 h. Cell viability was determined using an MTT based assay. MTT (5 mg mL<sup>−1</sup> in PBS, 10 µL) was added to the cells and incubated for 4 h. The resulting formazan crystals were dissolved with 50 µL of 1 : 1 (v/v) DMSO/methanol. Absorbance was determined with a microplate reader (ELISA) at 550 nm wavelength.

### 2.7 Animals

C57BL/6J male mice (6–8 weeks old, each weighing ~20–22 g) were purchased from the National Institute of Nutrition, Hyderabad, India. All *in vivo* experiments were performed strictly according to the guidelines provided by the statutory Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) [Chapter 4, Section 15(1) of the Prevention of Cruelty to Animals Act 1960, India]. The animal protocol [no. IICT/BMG/RKB/28/09/2015/03] was approved by the 'Institutional Animal Ethical Committee' (IAEC) of CSIR-Indian Institute of Chemical Technology, Hyderabad, India [Registration no. 97/GO/RBi/S/1999/CPCSEA, dated 1-Oct-2015].

### 2.8 Orthotopic brain tumor implantation and a subcutaneous model for treatment

An orthotopic model was established using an earlier reported method.<sup>24</sup> In brief, 4–6 week old male C57BL/6J mice were anaesthetized by intra-peritoneal injection of a ketamine–xylazine mixture. Using a 5 µL Hamilton syringe,  $1.5 \times 10^4$  cells suspended in 3 µL of phosphate buffered saline (PBS) were stereotactically injected through an entry site at the bregma (2 mm to the right of the sagittal suture and 3 mm below the surface of the skull) using a stereotactic frame (Harvard Apparatus, USA). Animals were observed every day after tumor cell challenge, and mice that developed symptoms indicative of brain tumors such as paralysis, lethargy, or wasting symptoms were euthanized. In C57BL/6J mice, a subcutaneous model was developed by inoculating  $5 \times 10^5$  GL261 cells in the left, lower abdomen of each mouse. When the tumor size reached 100 mm<sup>3</sup> the mice were divided into 4 different groups and treatment with CFD, CD, free DOX and 5% glucose (untreated) started on alternate days with injection of overall 5 doses of DOX at an amount of 5 mg kg<sup>−1</sup>.

### 2.9 *In vivo* imaging

The glioma bearing mice were established as described above. After tumor inoculation, on the 10th day 2 mg kg<sup>−1</sup> DiR-loaded CSPs or CF8 was intraperitoneally injected into glioma tumor bearing ( $n = 3$ ) mice. The distribution of fluorescence was observed using an IVIS Spectrum (PerkinElmer) *in vivo* imaging system after anaesthetising the animals. At 6 h and 24 h post injection, the *in vivo* images of intact animals were taken. Mice were then euthanized *via* CO<sub>2</sub> overdose and organs (brain,



heart, lungs, liver, spleen, and kidneys) were excised and imaged using the IVIS Spectrum.

## 2.10 Immunohistochemical studies

For immunochemistry studies, mouse brains obtained from doxorubicin conjugated CSPs and CSP-FA8 treated glioma-bearing mice ( $n = 3$ ) were fixed with 4% formaldehyde overnight, washed with PBS and stored in 20% glycerol solution (PBS). 10 micron frozen tissue sections were prepared with a Leica tissue sectioning biosystem. For folate receptor (FR) staining studies, the sections were rinsed with PBS for 10 min followed by incubation with 0.5% Triton X-100 in PBS for 60 min at room temperature. Slides were kept in a blocking solution of 5% BSA and 5% NHS with 0.5% Triton X-100 in PBS for 1.5 h. Then the sections were incubated with rabbit anti-FR (1 : 200) in the blocking solution overnight at 40 °C. After bringing the sections to RT and resting for 30 min, the sections were rinsed with PBST (0.1% Tween-20) 4 times each for 10 min. Then the sections were incubated with FITC labelled goat anti-rabbit antibody (1 : 500) for 2 h at RT followed by rinsing with PBST-20 four times. DAPI, 2  $\mu\text{g mL}^{-1}$ , was added to the sections and they were mounted with cover slips. The distribution of fluorescence was observed using an FV10i confocal microscope (Olympus).


## 2.11 Tumor associated macrophage (TAM) isolation and *ex vivo* uptake studies

Tumor associated macrophage isolation was performed following a procedure reported earlier.<sup>25,26</sup> In brief, C57BL/6J mice were subcutaneously implanted with  $5 \times 10^5$  GL261 cells. After 20 days, when the tumor size reached 1500 mm<sup>3</sup>, the mice were separated into three groups and treated with CFD, CD and DOX. After 8 h, tumors were isolated and tumor associated macrophages collected according to a standard protocol.

The tumors were cut into small pieces and 10 mL of digestion medium (containing collagenase) was added. The erythrocytes were removed by treating the cell mass with erythrocyte lysis buffer, centrifuging and removing the supernatant. For isolating tumor associated macrophages, the above pellet was resuspended in MACS buffer and magnetic bead-conjugated antibodies (Miltenyi Biotec) against the CD11b surface marker were added at a concentration of 10  $\mu\text{L}/10^7$  cells. The cell suspension was added to a MACS LS column and placed under a magnetic field. The unbound cells were washed off, and the bound CD11b<sup>+</sup> macrophages were isolated by removing the magnetic field. These unbound cells are the heterogeneous population of many kinds of tumor mass-associated cells, such as malignant cancer cells, tumor associated endothelial cells, fibroblasts, DCs *etc.* These TAM-free tumor cells were also preserved for estimating FR expression levels and for uptake studies. For *in vivo* uptake studies, GL261 subcutaneous tumor bearing mice ( $n = 3$ ) were given single intraperitoneal injections of either DOX, DOX conjugated CSPs or CSP-F8. After 18 h tumors were isolated, and TAMs from tumor were analysed through flow cytometry (BD FACS Canto II).

## 2.12 Anti-glioma effect

An orthotopic model was established using the above method. After tumor implantation (day 0), on day 4, tumor bearing mice were randomly sorted into four groups. Each group ( $n = 6$ ) was administered DOX, DOX conjugated CSPs and CSP-FA8 through intra-peritoneal injections. For the subcutaneous model,  $5 \times 10^5$  GL261 cells in 200  $\mu\text{L}$  of PBS were injected in the right flank of mice on day 0. After 12 days, the mice were divided into 4 groups ( $n = 5$ ). Each group was administered DOX, DOX conjugated CSPs and CSP-F8 separately *via* intra-peritoneal injections. The untreated group was administered 5% glucose only. Each mouse received five doses on every alternate day.



**Fig. 1** (A) Size of CFD and CD measured with DLS. (B) SEM images of CFD and CD. CD represents CSP-DOX and CFD represents CSP-F8-DOX. (C) Table shows the size and charge of various carbon nanospheres. CSP represents pristine, non-functional carbon nanospheres; CF8 represents CSP conjugated with F8, CD represents CSP conjugated with DOX, CFD represents CSP simultaneously conjugated with F8 and DOX, CC8-D represents CSP conjugated with C8 lipid and DOX, CFA-D represents CSP conjugated with folic acid (FA) and DOX and CC8 represents CSP conjugated with C8 lipid.





Tumor volumes were measured with slide calipers and calculated using the  $\frac{1}{2} \times a \times b^2$  formula, where 'a' is the longest dimension and 'b' is the shortest. Mice were observed thereafter for survivability.

### 2.13 Western blot study and chemokine profile analysis

All the tumors from the mice belonging to the respective treatment or untreated groups (*i.e.*, DOX, CD, CFD and untreated) were isolated and pooled, and lysates were prepared. After homogenization of tumor tissues in  $1 \times$  PBS, Triton X-100 was added to 1% final concentration and the tissues were kept on ice for 10 min. Centrifugation was performed at 10 000 rpm for 10 min at 4 °C. Quantification of protein in lysates was carried out using the BCA method. Proteins and chemokines were analysed using Western blot and a mouse cytokine array, respectively.

### 2.14 H & E staining for histology analysis

The acute toxicity of the formulation in various organs such as the heart, liver, kidney *etc.* was histologically examined following a single injection of CFD to mice. 24 h post treatment, the collected organs were frozen using the Leica tissue freezing medium (Leica, Germany). The frozen tissues were sectioned with a thickness of 5 microns using a Leica CM1850 Instrument (Leica Microsystem, Germany). The sections were imaged in

bright field using a Nikon Eclipse TE2000 microscope (Nikon, Japan) following tissue staining with hematoxylin & eosin (H & E).


### 2.15 Statistical analysis

Error bars represent mean values  $\pm$  SD. The statistical significances of the samples were determined using the two-tailed Student's *t*-test, Graph Pad Prism software. *p* values less than 0.05 were considered to be statistically significant.

## 3. Results

### 3.1 Synthesis and characterization of CSP conjugates

The F8 structure [Scheme 1] was designed to accommodate a dioctyl methyl ammonium moiety in the distal end of the carboxylic group, which is often used for folate ligand conjugation. Synthesis of F8 was accomplished as per a synthetic protocol described earlier.<sup>14</sup> The C8 control molecule was prepared (ESI Scheme S1†) and characterized through <sup>1</sup>H NMR and ESI mass spectrometry. CSPs were then simultaneously associated with F8 and DOX, or only DOX. These were then reconstituted in aqueous solution [Scheme 1]. The hydrodynamic diameters (size) and surface charges (zeta potential) of different CSP conjugates were measured using a Zetasizer. The sizes of CSP-F8-DOX (CFD) and CSP-DOX (CD), respectively, are in the range of 360 nm (Fig. 1A). The polydispersity index (PDI) of such CSP conjugates is less than 0.3, thereby clearly indicating the fairly homogeneous size distribution of CSP



**Fig. 2** Cellular uptake of doxorubicin (DOX) and viability studies in cancer and non-cancer cells. (A) Microscopy images of mouse glioma GL261 cells treated with CFD, CD and pristine DOX. (B and C) Flow cytometric analysis of glioma cells treated with CFD (green), CD (red), DOX (black), CC8-D (pink) and CFA-D (blue, FA denotes folic acid). (D and E) Cytotoxicity profiles of different DOX-conjugated CSPs in GL261 cancer cells and NIH-3T3 non-cancer cells.



conjugates (Fig. 1C). IR spectra of CSPs and their conjugated products indicate the association of ligands and/or drugs on CSPs (Fig. S1†). The size of DOX and F8-conjugated CSP [i.e., CFD] is stable up to 48 h in 50% serum in PBS (Fig. S2†). Additionally, SEM images show a homogeneously spherical structure of CFD and CD conjugates (Fig. 1B). The surface charges of different conjugates [CSP, CSP-F8 (CF8), CFD, CD, CFA-D, and CC8-D] are in the range of  $-22$  to  $-37$  mV (Fig. 1C). The mol% of F8 associated with the surface of CSPs was measured by calculating residual F8 un-associated (measured from F8 absorbance max at 284.5 nm) with CSPs. The associated F8 is  $\sim 22\%$  (w/w) with respect to CSPs. The zeta potential measurement data indicate that the association of the cationic folate ligand F8 significantly reduced the negative surface charge of CSPs. DOX entrapment on CSP-F8 and CSP surfaces was in between 50 and 60% with respect to the weight of CSPs. The DOX and F8 entrapment or association efficiencies with CSPs are calculated based on standard curves [Fig. S3–S5†].


### 3.2 F8 enables FR-mediated cellular uptake of CSPs in GL261 cells

Cellular uptake studies of either free DOX, DOX associated CSP-F8 [i.e., CFD] or CSP [i.e., CD] were conducted in mouse glioma GL261 cells following 3 h of treatment using fluorescence microscopy and flow cytometry. Results visually show that the DOX uptake is higher in CFD-treated GL261 cells than in cells

treated with CD (Fig. 2A). Flow cytometric uptake data also reveal the highest red fluorescence shift in CFD treated GL261 cells (indicated with green in Fig. 2B) compared to the shifts obtained from cells treated with CD and DOX. Hence, the presence of the F8-ligand helped CFD to gain better access in GL261 cells. However, to test whether F8 or folic acid (FA) is better in enabling efficient cellular uptake, we compared the cellular uptake of FA-associated CD (i.e., CFA-D) with that of CFD using flow cytometry analysis. Fig. 2B (2nd panel) shows that the cellular uptake of CFD is more than that of CFA-D. This clearly indicates that F8-association rather than FA-association helps to achieve better cellular uptake of nanospheres. This also corroborates our logic of designing the cationic lipid–folic acid conjugate, which seemingly shows stronger affinity for FR-expressing GL261 cells. Among all, the uptake of CFD in GL261 cells is significantly inhibited in the presence of folic acid, indicating that its uptake is truly FR-mediated (Fig. 2C).

### 3.3 CFD shows efficient and selective cancer cell killing

The cellular cytotoxicities of DOX-associated, FR-targeting carbon nanospheres (CFD) and non-targeting carbon nanospheres (CD) and free DOX were evaluated and compared in GL261 cells and in non-cancerous fibroblast NIH 3T3 cells using the standard MTT assay. CFD shows the lowest IC<sub>50</sub> at 400 nM in FR-positive GL261 cells. The IC<sub>50</sub> values of CD ( $\geq 2.5$   $\mu$ M) and free DOX ( $\geq 2$   $\mu$ M) were significantly higher than that of CFD in



**Fig. 3** Comparison of *in vivo* accumulation of FR-targeting and non-targeting carbon nanospheres in orthotopic GL261 tumor bearing C57BL/6 mice following IP injections. Here CSPs are further conjugated with either an NIR dye (DiR) or DOX. (A) NIR-imaging of the brain region of mice treated with DiR-labeled CSP-F8 (CSP-F8-DiR) and CSP (CSP-DiR) after 6 h and 24 h of treatment. The graph represents the uptake and comparison of quantified DiR dye in the brain of mice treated with CSP-F8-DiR and CSP-DiR, respectively ( $n = 3$ ).  $**p < 0.01$ . (B) Bio-distribution profiles of DiR-conjugated CSPs and CSP-F8 in different organs including the brain excised after sacrificing the mice from respective treatment groups after 6 h and 24 h. The graph represents the comparison of brain uptake in different treatment groups at different time points ( $n = 3$ ).  $*p < 0.05$ .



GL261 cells indicating that CFD is a most potent cytotoxic material, more potent than even free DOX *in vitro* (Fig. 2D). Moreover, the cytotoxic effects of these materials were also checked in FR-negative NIH 3T3 cells. No cellular toxicities were noticed following the treatment with CFD, CD or DOX (Fig. 2E). Overall, the data imply that CFD is the most potent and selective cytotoxic material among other nanospheres.

### 3.4 CF8 accumulates with higher efficiency than CSPs in orthotopic glioma tumors developed in mice

Next, we wanted to examine the uptake of CF8 in orthotopic glioma tumors in mice. For this, an NIR dye (DiR) was conjugated with CSPs and CF8. Tissue distributions of CF8-DiR and CSP-DiR were examined in orthotopic GL261 tumor bearing C57BL/6J mice by quantifying the amount of visible dye. The nanomaterials were injected intra-peritoneally in mice at two different time points (6 h and 24 h) and the distribution patterns of nanomaterials in the brain and other organs at these two time points were obtained. Fig. 3A shows that the accumulation of the nanomaterial CF8-DiR is significantly higher than that of CSP-DiR in the brain at both time points. After *ex vivo* harvesting of different organs followed by an external washing of organs (*e.g.*, brain) with PBS, we noticed that the uptake of nanoparticles in the brain was reduced relative to what was observed during live conditions. Even then, the brain uptake of CF8-DiR was significantly higher than that of CSP-DiR in all time points tested (Fig. 3B).

The accumulated amounts of nanomaterials in the brain (Fig. 3A and B) were decreased for both CF8-DiR and CSP-DiR 24 h later. Notably, even though the amounts of nanoparticle uptake in the brain are different, the uptake amounts of CF8-DiR and CSP-DiR in other organs were similar (Fig. 3B). To substantiate the notion that the observed bio-distribution pattern is because of nanoparticle-associated DiR and not because of free DiR *in vivo*, we injected free DiR dye intraperitoneally and found a completely different picture. Free DiR dye remains largely localized to its point of injection and even after 24 h one can observe its negligible presence in the brain (Fig. S6†), thus assuring that the bio-distribution in Fig. 3 is due to nanoparticle-associated DiR. The overall data clearly indicate that F8-conjugated nanomaterial has the propensity to have higher brain accumulation than non-targeting nanomaterials. As F8 exhibits affinity for FRs, and glioma cells implanted in the brain naturally express FRs, there is a possibility that this condition has led to enhanced brain accumulation of CF8-DiR compared to CSP-DiR.

### 3.5 Enhanced accumulation of CFD in FR-expressing glioma lesions in the brain

Next, we wanted to confirm if DOX-associated nanomaterials (CFD and CD) behaved similarly to NIR dye associated nanomaterials. On the 10th day, after orthotopic GL261 tumor implantation in the brain, mice were divided into three groups ( $n = 3$ ) and separately injected with a single dose of DOX, CFD or CD. After 18 h, mice were sacrificed to collect brains and they were cry-sectioned for immunohistochemical analysis. It was

noticed that the CFD-accumulation (red) in the brain was significantly more than CD-accumulation, especially in FR-expressing regions (green) in the brain (Fig. 4A). Free DOX-accumulation in the brain was visually negligible in FR-expressing brain tumor regions. As a matter of fact, the FR-expression level was checked in non-tumor regions of the brain. It was found that the FR-expression was too low to detect properly, indicating that only cells in the brain tumor regions express FRs (Fig. 4B). Notably, in the non-tumor region, an almost negligible amount of CFD accumulation was observed (Fig. 4B). The overall data show that CFD accumulation is significantly higher than CD accumulation in the FR-expressing tumor region. The data are important as specific delivery of drug molecules to the tumor region and not to the non-cancer region is the most sought after observation in chemotherapy.

### 3.6 Isolation of TAMs and estimation of FR expression in TAM population obtained from the tumor microenvironment

Tumor associated macrophages (TAMs), which express FRs, play a predominant role in cancer progression, invasion and metastasis.<sup>16</sup>





Fig. 4 Comparison of *in vivo* accumulation of DOX containing FR-targeting (CFD) and non-targeting carbon nanospheres (CD), and simple DOX in brain sections of orthotopic GL261 tumor bearing mice following IP injections. (A) Confocal fluorescent images of tumor-bearing brain sections obtained from mice treated, respectively, with CFD, CD and DOX. The top panel shows the merged image of blue (DAPI, nuclear staining), green (FR expression) and red (DOX accumulation) fields and the bottom panels are images, respectively, obtained in green and red fields. (B) FR expression level and accumulation of CFD in CFD treated mice in the tumor-free region of the brain. Lower panels are green (FR expression, left panel) and blue (DAPI/nuclear staining, right panel) fields, and the upper panel is a merged image of green and red fields. (C) Quantification of red fluorescence in non-tumor and tumor regions of mice separately treated with CFD, CD, and DOX.



We hence intended to find out if an FR-targeting nanomaterial (CFD) has any selective uptake in TAMs. For this study, isolation of TAMs from the GL261 tumor was essential. Since the tumor size in the orthotopic mouse brain is very small, the isolation of TAMs from the *in situ* brain tumor is difficult. So, TAMs were isolated from a subcutaneous GL261 tumor in mice using an antibody against the TAM marker CD11b. The TAM isolation (Fig. 5A) was performed using CD11b antibody-labelled magnetic beads. First, surface markers of TAMs in the magnetically separated CD11b<sup>+</sup> TAM cell fraction were checked. This was followed by the examination of expression markers such as F4/80 and CD68 (Fig. 5B), which are established macrophage markers.<sup>27</sup> Most importantly, no expression of LY6C and low expression of MHC-II (here, no initial shift was observed) were found, which characteristically represents alternatively activated (M2) macrophages (or TAMs) that are

immunosuppressive and tumor promoting in nature.<sup>28</sup> In contrast, cell populations exhibiting combinations of high LY6C, low MHC-II inflammatory monocytes, or high LY6C, high MHC-II immature macrophages, or intermediate LY6C, high MHC-II represent classically activated M1 macrophages; all these cells possess the ability to eradicate tumors.<sup>28</sup> Hence, CD11b<sup>+</sup> TAMs isolated from the GL261 tumor were cross-checked for the extent of expression of FRs and F4/80 in these cells by flow cytometry, and the status of CD11b<sup>+</sup>/FR<sup>+</sup> and F4/80<sup>+</sup>/FR<sup>+</sup> populations was analysed, respectively (Fig. 5C). It was observed that 41–44% of total TAMs have these two populations, indicating that the FR-positive population among CD11b<sup>+</sup> TAMs is indeed real. We also find that the glioma lesions in brain sections do express F4/80, indicating the presence of TAMs in the brain (Fig. S7†). As TAMs also express FRs, it is logically expected that TAMs in the brain could be targeted through their expressed FRs using CFD.



**Fig. 5** FR-targeting carbon nanospheres locate in tumor associated macrophages (TAMs) in the tumor environment obtained from the subcutaneous GL261 tumor model. The TAMs are isolated using magnetically labeled CD11b-associated microbeads. (A) Scheme showing the separation method for TAM isolation from a solid tumor. (B) Flow cytometric analyses of tumor-associated surface marker expressions on TAMs isolated from a subcutaneous GL261 tumor in mice. Expression levels of different surface markers (red) on TAMs and their corresponding subtype IgG controls (black) are represented accordingly. (C) The percentages of CD11b<sup>+</sup> and F4/80<sup>+</sup> macrophages simultaneously expressing FRs. (D) Flow cytometric analysis of TAMs isolated from tumor-bearing mice treated with CFD (green), CD (red) and DOX (black). (E) Flow cytometric analysis of differences in CFD uptake in TAMs (green) and TAM-free, isolated tumour cells (blue) from the tumor-bearing mice. (F) Flow cytometric analysis to exhibit the differences in FR-expression levels in TAMs (green) and TAM-free, isolated tumour cells (blue) from the tumor-bearing mice. (G) Confocal microscopy images of TAMs isolated from CFD-, CD- or DOX-treated tumor-bearing mice.

### 3.7 CFD accumulates in TAMs *in vivo*

For this study, after subcutaneous GL261 tumor inoculation, when the tumor size reached 1500 mm<sup>3</sup> volume, mice were divided into three groups and separately treated with CFD, CD or free DOX. After 12 h, CD11b<sup>+</sup> TAMs were isolated from tumors of sacrificed mice in different treatment groups. The extent of uptake of DOX in TAMs from different treatment groups was analysed by flow cytometry. Higher uptake of DOX was obtained in TAMs from CFD-treated mice. Uptake of CD and free DOX in TAMs was much lower compared to CFD-uptake (Fig. 5D). Incidentally, the amounts of uptake of CD and free DOX in TAMs are similar. We further compared the uptake of CFD in TAMs and in isolated tumor cells. For this, CD11b-void cells were separately isolated. These cells are a heterogeneous mixture of all tumor-associated cells except TAMs. Clearly the uptake of CFD is more in TAMs than in tumour cells (Fig. 5E). This is corroborated by the observation that the FR expression is also evidently higher in TAMs than in tumour cells (Fig. 5F). Thus, the uptake of CFD is more or less directly proportional to the FR expression level. Additionally, the uptake pattern of CFD, CD and DOX (shown in Fig. 5D) was also confirmed by fluorescence microscopy images of isolated TAMs from mice of respective treatment groups (Fig. 5G). Clearly, these FR-positive TAMs treated with CFD have higher propensity to take up DOX. Virtually, the uptake of CD and DOX in these TAMs was significantly low. From Fig. 5B, C and F it is clear that TAMs express FRs, possibly even more than the gross tumor cells, and CFD by virtue of the FR-targeting ligand F8 is selectively and efficiently taken up by these TAMs.

### 3.8 Tumor growth inhibition study

Further, with a view to examine the efficacy of the orthotopic tumor growth inhibitory effect of the TAM and tumor cell (dual) targeting CFD system orthotopic GL261 glioma bearing mice were developed. On day 4, post orthotopic tumor implantation in the brain, mice were randomly divided into four groups ( $n = 6$ ) and separately administered CFD, CD, free DOX or 5% glucose (untreated control group) intraperitoneally on every alternate day






with a total of five doses. The DOX amount so injected in all treated groups was maintained at  $5 \text{ mg kg}^{-1}$  body weight of mice in all doses. Importantly, mice treated with CFD had significantly improved survivability compared to mice in untreated and other treated groups (Fig. 6A). We believe that this enhanced survivability of CFD-treated orthotopic tumor bearing mice was presumably due to the dual targeting effect of DOX associated CFD on FR-expressing tumor cells and TAMs. For visibly assessing the effect of CFD on the tumor mass, we performed an *in vivo* tumor regression study in subcutaneous GL261 tumor-bearing mice. After 12 days of subcutaneous tumor inoculation, mice were divided into 4 groups ( $n = 5$ ) and treated separately similar to the above-mentioned treatment groups, and the mouse survivability was observed. It is clear that CFD treated mice have the highest overall survivability compared to other treatment groups (Fig. 6B). Fig. 6C shows the trend of subcutaneous tumor regression over 22 days, after which mice were sacrificed and tumors from different groups were harvested and their sizes were compared (shown on the top of Fig. 6C). The visual comparison of tumor sizes conforms with the respective tumor volume (Fig. 6D), which proves the efficient *in vivo* effect of CFD on tumor targeting and tumor-regression ability.

### 3.9 Western blot and cytokine profile analysis

Next, in order to investigate the dual targeting effects of CFD in the tumor microenvironment, Western blot and cytokine profile analyses were performed on tumor lysates obtained from tumors of orthotopic GL261 glioma mice ( $n = 3$ ) treated with CFD, CD, free DOX or 5% glucose (UT). Western blot analysis (Fig. 6E)

shows that the expression of TGF- $\beta$  and STAT-3 was prominently reduced by CFD. These proteins, typically expressed by TAMs, help tumor-associated cells' proliferation and invasion.<sup>10,29</sup> Cytokine profile analysis of tumor lysates shows the changes in the expression of certain common cytokines. In comparison to the untreated sample, CFD treatment led to a decrease in the expression of macrophage-released cytokine C5a and another cytokine released by tumor epithelial cells called sICAM-1, which are involved in tumor progression.<sup>30–34</sup> In contrast, CFD also mediated the increase of certain tumor-inhibiting cytokines such as IL-1 $\alpha$  and IP-10 (Fig. 6F). As IL-1 is involved in tumor invasiveness and angiogenesis,<sup>34</sup> the antagonist to the IL-1 receptor, *i.e.*, IL-1 $\alpha$  which is expressed by immune cells, epithelial cells *etc.*, antagonizes the IL-1-mediated tumor aggressiveness and pro-inflammation.<sup>35,36</sup> Further, the IFN- $\gamma$ -induced protein (IP10; also referred to as CXCL10), which is produced mostly from immune cells besides epithelial cells due to innate and adaptive immune responses, is associated with anti-tumorigenic angiostatic properties, involved in the recruitment of NK cells in tumor masses *etc.*<sup>37,38</sup> Clearly, CFD treatment leads to the suppression (*e.g.*, C5/C5a and sICAM-1) or up-regulation (*e.g.*, IL-1 $\alpha$  and IP-10) of cytokines in tumor masses pointing toward specific anti-cancer activity of the FR-targeting CFD formulation in tumor masses and tumor associated macrophages. Importantly, these data are corroborated in tumor-bearing brains also. The lysates of tumor-bearing brains from mice treated with the above-mentioned compounds also show that CFD indeed induced decreased expression of sICAM-1 and C5/C5a compared to other treatment groups [Fig. S8†].



**Fig. 6** FR-targeting nanospheres inhibit tumor growth in mice. (A) Cumulative survival study of orthotopic GL261 brain tumor bearing mice after treatment with CFD, CD or pristine DOX on days 4, 6, 8, 10 and 12 after tumor cell inoculation. UT represents the group treated with 5% glucose. In all DOX-treated groups the amount of DOX was  $5 \text{ mg kg}^{-1}$  body weight of mice. (B) Cumulative survival study of subcutaneous GL261 tumor bearing mice after CFD, CD, DOX treatments. UT represents 5% glucose treatment. (C) Graph indicates the tumor regression curve after subcutaneous GL261 tumor inoculation followed by respective treatments for the represented groups on days 12, 14, 16, 18 & 20. The image represents tumors obtained from mice treated with 5% glucose, DOX, CD and CFD 22 days after inoculation of cells subcutaneously. (D) Subcutaneous tumor volume of indicated treatment groups after five treatments followed by sacrificing of mice on day 22 from the day of subcutaneous inoculation of GL261 cells in C57BL/6J mice. (E) Expression of TGF- $\beta$  and STAT-3 with respect to  $\beta$ -actin in brain tumor-lysates from mice treated with 5% glucose (UT), DOX, CD and CFD, respectively. (F) Levels of various chemokines in brain tumor ( $n = 3$ ) lysates obtained from mice treated with 50% glucose (UT), DOX, CD and CFD, respectively.

### 3.10 Histology analysis using H & E staining

Histology analyses of various organs of mice were performed. Organs such as the liver, heart and spleen were harvested from sacrificed mice IP injected with single injection of either CFD or PBS. Harvested organs were sectioned and stained with hematoxylin and eosin (H & E). The respective sections from two different groups were compared. The section images (Fig. 7) of CFD-treated mice showed no distinct or perceptible changes in physiological characteristics of organ-tissues as these were comparable to those of tissues obtained from PBS-treated mice. No tissue damage following CFD treatment indicates that CFD possibly has no short-term, non-specific toxicity to vital organs such as the liver during the course of treatment.

## 4. Discussion

In spite of significant preclinical and clinical research toward developing efficient therapeutics against glioma the enhancement of overall survivability in glioma subjects and patients still remains challenging. Targeting the brain through the BBB was accomplished by targeting through various receptors. The nicotinic acetylcholine receptor is one such example, which is over-expressed on brain endothelial cells and neuromuscular junctions in the CNS.<sup>39–41</sup> Using a D-peptide ligand to target these receptors for delivering doxorubicin Wei *et al.* reported a less than 1.5 times increase in median survivability of glioma nude mice compared to the median survivability of the untreated group.<sup>42</sup> Cyclic RGD shows affinity for various integrin receptors over-expressed on glioblastoma and tumor-associated endothelial cells.<sup>43</sup> Although controversial about how to target *in situ* glioblastoma through the BBB, Miura *et al.* reported cyclic RGD-based polymeric micelles with a platinum-based drug for glioblastoma regression in an orthotopic model

in mice.<sup>44</sup> These are representative examples to showcase how to target tumor-associated endothelial cells, but there is no evidence of targeting TAMs in brain tumor masses.

TAMs are functionally linked with the receptors that increase malignancy. Cytokines such as TGF- $\beta$  and IL-10 are frequently released in the TME and are implicated with polarization of M2 macrophages.<sup>45</sup> Recently, Karlsson *et al.* reported targeting the MARCO receptor on TAMs using an anti-monoclonal MARCO antibody based targeted therapy in breast and colon tumor-associated TMEs.<sup>46</sup> They reported antitumor activity resulting from reprogramming of TAM populations to become a pro-inflammatory phenotype, increasing immunogenicity in tumors. Herein, we demonstrate TAM targeting through the over-expressed folate receptor (FR). The FR is incidentally over-expressed on both TAMs and glioma cells. On this basis, we accomplished drug-delivery to tumor masses for effective tumor regression.

Carbon nanospheres (CSPs) are gaining more attention among carbon-based materials in biomedical applications. Selvi *et al.* reported these carbon nanospheres as a good candidate for crossing BBB and delivering drugs to the nucleus and intra-cellular compartments.<sup>14</sup> The folate receptor is over-expressed on several epithelial cancer cells. Corbi *et al.* reported that overexpression of the FR is found on TAMs having an M2 like functional profile while exerting immunosuppressive functions in the TME.<sup>16</sup> Hence, it could be logically hypothesized that upon association with the FR-targeting molecule (F8), the functional CSPs (*i.e.*, CF8) would be able to deliver the drug cargo not only within the brain but also selectively to FR-expressing glioma cells and TAMs after crossing the BBB. The CSPs, being negatively charged, electrostatically accommodate F8 and hence it is possible for them to carry excess ligands. This is one of the limitations of other conventional FR-targeting delivery systems such as liposomes. Because of the enhanced amount of F8, CF8 would experience enhanced affinity for the FR. Additionally, as the BBB also over-expresses the FR,<sup>47</sup> it is pertinent to think that CF8 would have relatively higher interaction with the BBB. In fact, it was found to be true as we observed 100-fold higher uptake of CF8 than CSPs in the brain area within 6 h. The uptake dissipated eventually by 24 h but by then the interaction with the BBB and eventual entry in the brain would ensure higher uptake of CF8 in the brain. As CF8 targets FRs, one can expect selective uptake of CF8 in FR-expressing glioma lesions. Further, CF8 upon conjugation with doxorubicin (*i.e.*, CFD) showed higher *in vitro* toxicity with enhanced cellular uptake in GL261 than that of the non-targeting CSPs.

To confirm CFD-mediated DOX delivery to TAMs especially through FRs, it was necessary to check the level of FRs in TAMs and the selective uptake of FR-targeting CFD in TAMs. Following CFD-treatment, CD11b<sup>+</sup> TAMs were isolated. The isolated TAMs showed maximum uptake for CFD compared to the non-targeting CSPs, which indicates that FRs on the TAM surface are functionally active for active drug transport. For the treatment of SLE disease, Philip S. Low and co-workers have shown that FR-positive macrophages adorned with folate-linked highly immunogenic 'haptens' are conveniently recognised and





Fig. 7 Representative H & E staining of sections of healthy organs (liver, heart and kidney) of mice. After 24 h of CFD administration, mice were sacrificed and organs were isolated. Sections were stained with H & E and compared with organ sections obtained from mice treated with only PBS. No perceptible tissue damage was demonstrated following CFD administration.





Scheme 2 CFD-mediated dual targeting of TAMs and malignant tumor cells.

destroyed by body's innate immune response.<sup>48</sup> This strategy was extended to cancer immunotherapy also.<sup>49</sup> It was also shown that activated macrophages express FRs and are hence used as drug targets. However, FRs are not expressed in F4/80+ peritoneal macrophages obtained from non-tumor associated models.<sup>50</sup> Our data show that TAMs obtained by using the marker CD11b<sup>+</sup> express FRs and also carry the F4/80 marker. This clearly indicates that simultaneous expression of FRs in tumor specific TAMs that bear the F4/80 marker is evident and is potentially useful for active drug targeting. But the important question would be to know if glioma tumor lesions also contain TAMs. This is important as the original idea is to deliver drugs to both tumor cells and TAMs in glioma lesions in the brain. Our data (Fig. S7†) show that brain sections carrying tumor lesions certainly express F4/80 which is one of the markers for macrophages. And as TAMs express FRs, it is expected that the region of tumor in the brain contains FR-expressing tumor cells and F4/80+ TAMs. Clearly, an FR targeting drug delivery system (here CFD) will have access to both TAMs and tumor cells in tumor masses *in situ*. Although it has been shown by FACS data that CFD gains access to TAMs, this example of active drug transport to TAMs especially for the glioma model, to the best of our knowledge, was not reported before.

One can notice that there is up-regulated FR expression in tumor regions in the brain section. Together with higher DOX uptake in the tumor-associated brain in CFD-treated mice, we believe it offers an additional advantage for FR-targeting anti-glioma therapeutics. This also substantiates the FR as a reliable prognostic marker useful for glioma treatment. CFD could increase the average survivability more than twice that of the untreated control, indicating possible adverse effects on glioma cells as well as TAMs in tumor lesions. The adverse effect on TAMs was evident by the change of levels of cytokines which are expressed mostly by immune cells.

TAMs express TGF- $\beta$ , which influences tumor-associated epithelial cells to proliferate *via* many pathways including the STAT-3 pathway. A decrease in TGF- $\beta$  followed by the STAT-3 level in the tumor lysate advocates the possibility that both TAMs and tumor cells are adversely affected by CFD. TGF- $\beta$  is known to induce EMT, which leads to metastasis. A decrease in TGF- $\beta$  evidently induces EMT reversal and reduces metastasis. Similar to the use of DOX as a model anticancer agent, any other potent drug, in combination with DOX or otherwise, that synergizes the EMT reversal can be used for a better preclinical outcome. Clearly, findings from this study open the door for a new targeting strategy which includes targeting both FR-expressing tumor associated macrophages and tumor cells with a single drug delivery system thereby promising an effective strategy against aggressive tumors such as glioblastoma. The targeting system bears promise in future for delivering multitude of drugs in combination for a better anti-tumor efficacy. Although there was no noticeable toxicity in CFD-treated mice, a complete toxicological evaluation is certainly due before the system is projected further for clinical trials.

## 5. Conclusion

In summary, we have developed a new, dual-targeting system using functional glucose-based carbon nanospheres for selective delivery of a model anti-cancer drug, doxorubicin. The system does not require FR-over-expression for targeting but can target even TAMs that moderately express FRs and malignant cells in tumor stroma. The simultaneous targeting and killing of TAMs and malignant cells by CFD is schematically described (Scheme 2). Findings from *in vitro* and *in vivo* experiments revealed clear therapeutic benefits for using this dual targeting strategy for simultaneously targeting both FR-expressing tumor cells and TAMs in the tumor





microenvironment. This viable strategy enables effective brain tumor regression and increased survivability.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was supported by funding from the CSIR-Mayo Clinic Partnership Grant (CMPP010), other CSIR network projects CSC0302, BSC0123, Govt. of India (to R. B.), and Department of Biotechnology sponsored project (BT/PR11756/NNT/28/764/2014) (to R. B. & T. K. K.), Department of Science and Technology, Nanomission Project (SR/NM/NS-1058/2015-JNCASR), Govt. of India (to T. K. K. and M. E, JNCASR). C. K. E. and K. S. acknowledge CSIR, and M. T. A. acknowledges DBT doctoral research fellowships, respectively. This is IICT communication no. IICT/Pubs/2018/102.

## References

- 1 R. Y. Bai, V. Staedtke and G. J. Riggins, *Trends Mol. Med.*, 2011, **17**, 301–312.
- 2 C. E. Lewis and J. W. Pollard, *Cancer Res.*, 2006, **66**, 605–612.
- 3 K. D. Elgert, D. G. Alleva and D. W. Mullins, *J. Leukocyte Biol.*, 1998, **64**, 275–290.
- 4 C. Sunderkötter, M. Goebeler, K. Schulze-Osthoff, R. Bhardwaj and C. Sorg, *Pharmacol. Ther.*, 1991, **51**, 195–216.
- 5 W. Zhou, S. Q. Ke, Z. Huang, W. Flavahan, X. Fang, J. Paul, L. Wu, A. E. Sloan, R. E. McLendon, X. Li, J. N. Rich and S. Bao, *Nat. Cell Biol.*, 2015, **17**, 170.
- 6 C. Murdoch, A. Giannoudis and C. E. Lewis, *Blood*, 2004, **104**, 2224–2234.
- 7 S. M. Pyonteck, L. Akkari, A. J. Schuhmacher, R. L. Bowman, L. Sevenich, D. F. Quail, O. C. Olson, M. L. Quick, J. T. Huse, V. Teijeiro and M. Setty, *Nat. Med.*, 2013, **19**, 1264–1272.
- 8 D. F. Quail, R. L. Bowman, L. Akkari, M. L. Quick, A. J. Schuhmacher, J. T. Huse, E. C. Holland, J. C. Sutton and J. A. Joyce, *Science*, 2016, 352.
- 9 H. Chong, Y. Vodovotz, G. W. Cox and M. H. Barcellos-Hoff, *J. Cell. Physiol.*, 1999, **178**, 275–283.
- 10 S. Wan, E. Zhao, I. Kryczek, L. Vatan, A. Sadovskaya, G. Ludema, D. M. Simeone, W. Zou and T. H. Welling, *Gastroenterology*, 2014, **147**, 1393–1404.
- 11 M. A. Miller, Y. R. Zheng, S. Gadde, C. Pfirschke, H. Zope, C. Engblom, R. H. Kohler, Y. Iwamoto, K. S. Yang, B. Askevold and N. Kolishetti, *Nat. Commun.*, 2015, **6**, 8692.
- 12 P. Zhang, Z. A. Qiao and S. Dai, *Chem. Commun.*, 2015, **51**, 9246–9256.
- 13 A. Nieto-Márquez, R. Romero, A. Romero and J. L. Valverde, *J. Mater. Chem.*, 2011, **21**, 1664–1672.
- 14 B. R. Selvi, D. Jagadeesan, B. S. Suma, G. Nagashankar, M. Arif, K. Balasubramanyam, M. Eswaramoorthy and T. K. Kundu, *Nano Lett.*, 2008, **8**, 3182–3188.
- 15 J. M. Saul, A. Annapragada, J. V. Natarajan and R. V. Bellamkonda, *J. Controlled Release*, 2003, **92**, 49–67.
- 16 A. Puig-Kröger, E. Sierra-Filardi, A. Dominguez-Soto, R. Samaniego, M. T. Corcuera, F. Gómez-Aguado, M. Ratnam, P. Sanchez-Mateos and A. L. Corbi, *Cancer Res.*, 2009, **69**, 9395–9403.
- 17 D. Cheng, N. Cao, J. Chen, X. Yu and X. Shuai, *Biomaterials*, 2012, **33**, 1170–1179.
- 18 N. Chen, C. Shao, Y. Qu, S. Li, W. Gu, T. Zheng, L. Ye and C. Yu, *ACS Appl. Mater. Interfaces*, 2014, **6**, 19850–19857.
- 19 Y. C. Chen, C. F. Chiang, S. K. Wu, L. F. Chen, W. Y. Hsieh and W. L. Lin, *J. Controlled Release*, 2015, **211**, 53–62.
- 20 H. Gao, Z. Yang, S. Zhang, S. Cao, S. Shen, Z. Pang and X. Jiang, *Sci. Rep.*, 2013, **3**, 2534.
- 21 J. Wang, Y. Yang, Y. Zhang, M. Huang, Z. Zhou, W. Luo and J. Tang, *Adv. Funct. Mater.*, 2016, **26**, 7873.
- 22 L. Zeng, L. Zou, H. Yu, X. He, H. Cao, Z. Zhang, Q. Yin, P. Zhang, W. Gu, L. Chen and Y. Li, *Adv. Funct. Mater.*, 2016, **26**, 4201–4212.
- 23 C. K. Elechalawar, K. Sridharan, A. Pal, M. T. Ahmed, M. Yousuf, S. S. Adhikari and R. Banerjee, *Biomater. Sci.*, 2017, **5**, 1898–1909.
- 24 H. Okada, H. Tahara, M. R. Shurin, J. Attanucci, K. M. Giezeman-Smits, W. K. Fellows, M. T. Lotze, H. Chambers and M. E. Bozik, *Int. J. Cancer*, 1998, **78**, 196–201.
- 25 L. Cassetta, R. Noy, A. Swierczak, G. Sugano, H. Smith, L. Wiechmann and J. W. Pollard, *Adv. Exp. Med. Biol.*, 2016, 211–229.
- 26 D. Laoui, E. Van Overmeire, J. Keirsse, K. Movahedi and J. A. Van, *Bio-Protoc.*, 2014, **4**, e1294.
- 27 J. G. Quatromoni and E. Eruslanov, *Am. J. Transl. Res.*, 2012, **4**, 376.
- 28 R. Noy and J. W. Pollard, *Immunity*, 2014, **41**, 49–61.
- 29 N. B. Hao, M. H. Lü, Y. H. Fan, Y. L. Cao, Z. R. Zhang and S. M. Yang, *Clin. Dev. Immunol.*, 2012, 2012.
- 30 J. Panse, K. Friedrichs, A. Marx, Y. Hildebrandt, T. Luetkens, K. Bartels, C. Horn, T. Stahl, Y. Cao, K. Milde-Langosch and A. Niendorf, *Br. J. Cancer*, 2008, **99**, 930.
- 31 H. Nitta, Y. Murakami, Y. Wada, M. Eto, H. Baba and T. Imamura, *Oncol. Rep.*, 2014, **32**, 1715–1719.
- 32 C. Rosette, R. B. Roth, P. Oeth, A. Braun, S. Krammerer, J. Ekblom and M. F. Denissenko, *Carcinogenesis*, 2005, **26**, 943–950.
- 33 B. A. Teicher and S. P. Fricker, *Clin. Cancer Res.*, 2010, **16**, 2927–2931.
- 34 Y. Gong, E. Scott, R. Lu, Y. Xu, W. K. Oh and Q. Yu, *PLoS One*, 2013, **8**, e77366.
- 35 E. Voronov, D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello and R. N. Apte, *Proc. Natl. Acad. Sci.*, 2003, **100**, 2645–2650.
- 36 S. Perrier, F. Darakhshan and E. Hajdudch, *FEBS Lett.*, 2006, **580**, 6289–6294.
- 37 J. A. Belperio, M. P. Keane, D. A. Arenberg, C. L. Addison, J. E. Ehler, M. D. Burdick and R. M. Strieter, *J. Leukocyte Biol.*, 2000, **68**, 1–8.



- 38 K. Kajitani, Y. Tanaka, K. Arihiro, T. Kataoka and H. Ohdan, *Breast Cancer Res. Treat.*, 2012, **134**, 139–155.
- 39 P. Kumar, H. Wu, J. L. McBride, K. E. Jung, M. H. Kim, B. L. Davidson, S. K. Lee, P. Shankar and N. Manjunath, *Nature*, 2007, **448**, 39.
- 40 S. Son, W. Hwang do, K. Singha, J. H. Jeong, T. G. Park, D. S. Lee and W. J. Kim, *J. Controlled Release*, 2011, **155**, 18–25.
- 41 C. Zhan, Z. Yan, C. Xie and W. Lu, *Mol. Pharm.*, 2010, **7**, 1940–1947.
- 42 X. Wei, C. Zhan, Q. Shen, W. Fu, C. Xie, J. Gao, C. Peng, P. Zhang and W. Lu, *Angew. Chem., Int. Ed.*, 2015, **54**, 3023–3027.
- 43 J. S. Desgrosellier and D. A. Cheresh, *Nat. Rev. Cancer*, 2010, **10**, 9–22.
- 44 Y. Miura, T. Takenaka, K. Toh, S. Wu, H. Nishihara, M. R. Kano, Y. Ino, T. Nomoto, Y. Matsumoto, H. Koyama, H. Cabral, N. Nishiyama and K. Kataoka, *ACS Nano*, 2013, **7**, 8583–8592.
- 45 F. O. Martinez, L. Helming and S. Gordon, *Annu. Rev. Immunol.*, 2009, **27**, 451–483.
- 46 A. M. Georgoudaki, K. E. Prokopec, V. F. Boura, E. Hellqvist, S. Sohn, J. Östling, R. Dahan, R. A. Harris, M. Rantalainen, D. Klevebring and M. Sund, *Cell Rep.*, 2016, **15**, 2000–2011.
- 47 D. Wu and W. M. Pardridge, *Pharm. Res.*, 1999, **16**, 415–419.
- 48 B. Varghese, N. Haase and P. S. Low, *Mol. Pharm.*, 2007, **4**, 679–685.
- 49 Y. Lu, E. Segal, C. P. Leamon and P. S. Low, *Adv. Drug Delivery Rev.*, 2004, **56**, 1161–1176.
- 50 W. Xia, A. R. Hilgenbrink, E. L. Matteson, M. B. Lockwood, J. X. Cheng and P. S. Low, *Blood*, 2009, **113**, 438–446.

